These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30530703)

  • 21. Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy.
    Van Looy T; Wozniak A; Floris G; Sciot R; Li H; Wellens J; Vanleeuw U; Fletcher JA; Manley PW; Debiec-Rychter M; Schöffski P
    Clin Cancer Res; 2014 Dec; 20(23):6071-82. PubMed ID: 25316817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs).
    Lu Y; Mao F; Li X; Zheng X; Wang M; Xu Q; Zhu J; Li J
    J Med Chem; 2017 Jun; 60(12):5099-5119. PubMed ID: 28541695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
    Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
    Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
    Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO
    Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.
    Huynh H; Lee JW; Chow PK; Ngo VC; Lew GB; Lam IW; Ong HS; Chung A; Soo KC
    Mol Cancer Ther; 2009 Jan; 8(1):152-9. PubMed ID: 19139124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.
    Huang WK; Akçakaya P; Gangaev A; Lee L; Zeljic K; Hajeri P; Berglund E; Ghaderi M; Åhlén J; Bränström R; Larsson C; Lui WO
    Exp Cell Res; 2018 Oct; 371(1):287-296. PubMed ID: 30149002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.
    Ran L; Sirota I; Cao Z; Murphy D; Chen Y; Shukla S; Xie Y; Kaufmann MC; Gao D; Zhu S; Rossi F; Wongvipat J; Taguchi T; Tap WD; Mellinghoff IK; Besmer P; Antonescu CR; Chen Y; Chi P
    Cancer Discov; 2015 Mar; 5(3):304-15. PubMed ID: 25572173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Establishment and pathologic analysis of imatinib-resistant gastrointestinal stromal tumor xenografts].
    Zheng S; Wang XJ; Jia J; Pan YL; Tao DY; Lu HS; Huang KE
    Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):176-80. PubMed ID: 22800481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors.
    Gebreyohannes YK; Burton EA; Wozniak A; Matusow B; Habets G; Wellens J; Cornillie J; Lin J; Nespi M; Wu G; Zhang C; Bollag G; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Exp Med; 2019 May; 19(2):201-210. PubMed ID: 30523507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastrointestinal stromal tumors.
    Antonescu C
    Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor.
    Zeng S; Seifert AM; Zhang JQ; Cavnar MJ; Kim TS; Balachandran VP; Santamaria-Barria JA; Cohen NA; Beckman MJ; Medina BD; Rossi F; Crawley MH; Loo JK; Maltbaek JH; Besmer P; Antonescu CR; DeMatteo RP
    Mol Cancer Ther; 2017 Sep; 16(9):1954-1966. PubMed ID: 28611108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib.
    Chen W; Li Z; Liu H; Jiang S; Wang G; Sun L; Li J; Wang X; Yu S; Huang J; Dong Y
    Cell Death Dis; 2020 Mar; 11(3):198. PubMed ID: 32251287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
    Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
    Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
    Lasota J; Miettinen M
    Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST.
    Pilla Reddy V; Anjum R; Grondine M; Smith A; Bhavsar D; Barry E; Guichard SM; Shao W; Kettle JG; Brown C; Banks E; Jones RDO
    Clin Cancer Res; 2020 Jul; 26(14):3751-3759. PubMed ID: 32220888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
    Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
    Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.